|
Aug 8
|
Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears
|
|
Aug 8
|
Reason to worry the Fed won't cut rates after all
|
|
Aug 8
|
Trade Desk downgraded, Instacart upgraded: Wall Street's top analyst calls
|
|
Aug 6
|
Compugen Reports Second Quarter 2025 Results
|
|
Aug 6
|
Gilead Sciences (GILD) Reports Q2: Everything You Need To Know Ahead Of Earnings
|
|
Aug 4
|
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter?
|
|
Aug 4
|
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
|
|
Aug 4
|
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
|
|
Aug 4
|
GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?
|
|
Aug 4
|
Central Bank Outlook Lifts Wall Street Pre-Bell; Asia, Europe Up
|
|
Aug 1
|
Stocks to watch next week: BP, Diageo, Disney, Uber and WPP
|
|
Aug 1
|
Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors
|
|
Jul 31
|
Trump Talks Tough on Drug Prices but His Demands Have Softened
|
|
Jul 31
|
What Trump's Big Pharma CEO letters mean for drug pricing power
|
|
Jul 31
|
Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs
|
|
Jul 31
|
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Jul 31
|
Are Wall Street Analysts Bullish on Gilead Sciences Stock?
|
|
Jul 30
|
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
|
|
Jul 30
|
Infectious Disease Treatment Market Report 2025-2030 | Long-acting Injectables, Self-testing Kits, and Combination Therapies Fueling Growth
|
|
Jul 30
|
Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL
|